Skip to main content
Premium Trial:

Request an Annual Quote

Something Superior?


A new study published in Lancet Oncology says that the breast cancer drug letrozole reduces breast cancer recurrence rates and improves survival rates better than tamoxifen, reports The New York Times' Anahad O'Connor. The study involved 8,010 postmenopausal ER+ breast cancer patients who were randomly assigned to receive either letrozole — sold by Novartis under the brand name Femara — or tamoxifen for five years, or both drugs taken in sequence, letrozole for two years followed by tamoxifen for three or vice versa. After a follow-up of about eight years, the researchers found that women given letrozole after surgery had a 20 percent lower risk of breast cancer recurrence and were 21 percent less likely to die from cancer, compared with tamoxifen, O'Connor says. The combination treatment did not significantly lower likelihood of recurrence or death, she adds.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.